Experts say patient-centric opioid intervention before discharge from the hospital can cut overall opioid intake, while still ensuring a patient is satisfied and their pain is properly managed.
The U.S. Food and Drug Administration issued an emergency use authorization for simultaneous administration of monoclonal antibodies bamlanivimab and etesevimab to treat COVID-19 patients who meet specific criteria.
The U.S. Food and Drug Administration is evaluating the potential impact of SARS-CoV-2 viral mutations on authorized molecular tests.
The U.S. Food and Drug Administration released an AI/ML-Based Software as a Medical Device Action Plan, which outlines a detailed approach to ensuring the safety and efficacy of these technologies.
